Moderna
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
IE
US
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Moderna (MRNA) Business News
Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more
-
CalendarDateSuMoTuWeThFrSaSelected FilterNo selection
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna to pay up to $2.25B to settle COVID vaccine patent matter
2 High-Flying Stocks With More Upside to Buy and Hold
Moderna and Ross Stores Lead Stock Gainers on Wednesday
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
First Look: Target (TGT), Paramount (PSKY) and Gold in Focus
Moderna Stock Rallies. This Big Risk Just Got Eliminated.
Moderna Pops After Inking $950 Million Covid Vaccine Settlement
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
11:05 AM | Wednesday | Mar 4, 2026
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP technology, ensuring freedom to operate for its infectious disease and vaccine pipeline, including future combo vaccines. The settlement preserves MRNA's strong balance sheet, with projected 2026 liquidity of $5.4–$5.
9 billion, supporting pipeline expansion and breakeven target by 2028.
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
Seeking AlphaModerna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP technology, ensuring freedom to operate for its infectious disease and vaccine pipeline, including future combo vaccines. The settlement preserves MRNA's strong balance sheet, with projected 2026 liquidity of $5.4–$5.
9 billion, supporting pipeline expansion and breakeven target by 2028.
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Zacks Investment ResearchModerna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
Read full article
Moderna to pay up to $2.25B to settle COVID vaccine patent matter
Proactive InvestorsModerna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to $2.25 billion to settle a global patent infringement lawsuit brought by Arbutus Biopharma and Genevant Sciences over the use of lipid nanoparticle (LNP) delivery technology in its COVID-19 and RSV vaccines. The settlement resolves all US and international enforcement actions related to Moderna's use of Arbutus' and Genevant's LNP technology in Spikevax, its COVID-19 vaccine, and mRESVIA, its RSV vaccine.
Read full article
2 High-Flying Stocks With More Upside to Buy and Hold
The Motley FoolWalmart is expertly navigating a challenging retail environment while continuing to grow its dividend. Moderna has a promising candidate that could hit the market in the near future.
Read full article
Moderna and Ross Stores Lead Stock Gainers on Wednesday
24/7 Wall StreetTwo stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct catalyst.
Read full article
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
ReutersModerna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its pipeline.
Read full article
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
BenzingaModerna Inc. (NASDAQ: MRNA) shares are up during Wednesday's premarket session following a settlement agreement with Arbutus Biopharma Corporation (NASDAQ: ABUS) and Roivant Inc.'s (NASDAQ: ROIV) Genevant Sciences.
Read full article
First Look: Target (TGT), Paramount (PSKY) and Gold in Focus
GuruFocusStock News Wall Street whipsawed by Mideast turmoil: The SPDR S&P 500 ETF Trust (SPY) fell Tuesday, then futures steadied as oil volatility and safeâhaven flo
Read full article
Moderna Stock Rallies. This Big Risk Just Got Eliminated.
BarronsThe company settles to resove patent litigation related to its Covid-19 vaccine, removing an overhang for shares.
Read full article
Moderna Pops After Inking $950 Million Covid Vaccine Settlement
Investors Business DailyModerna settled a yearslong patent dispute with Arbutus Biopharma and a subsidiary of Roivant Sciences. The news sent Moderna shares jumping.
Read full article